Martin J. Glennie mainly investigates Monoclonal antibody, Antibody, Immunology, CD20 and Antigen. His studies in Monoclonal antibody integrate themes in fields like Biochemistry, Intracellular, Cell biology, Molecular biology and Cytotoxicity. Martin J. Glennie has included themes like Epitope, Epitope mapping and CD8 in his Molecular biology study.
His Antibody study combines topics from a wide range of disciplines, such as CD28 and Cytotoxic T cell. His Immunology study often links to related topics such as Cancer. His CD20 research integrates issues from Monoclonal, Virology, B cell, Rituximab and Chronic lymphocytic leukemia.
Martin J. Glennie mostly deals with Antibody, Monoclonal antibody, Immunology, Antigen and Molecular biology. His research in Antibody intersects with topics in Receptor and Effector, Cell biology. His research integrates issues of Cancer research, Immunotherapy, Epitope, In vivo and CD20 in his study of Monoclonal antibody.
His Cancer research study combines topics in areas such as Cancer and CD19. Martin J. Glennie works mostly in the field of Immunology, limiting it down to topics relating to Cytotoxic T cell and, in certain cases, CD8 and T cell, as a part of the same area of interest. In his study, Antigenic Modulation is inextricably linked to Idiotype, which falls within the broad field of Molecular biology.
The scientist’s investigation covers issues in Monoclonal antibody, Antibody, Immunology, Receptor and Cancer research. He has researched Monoclonal antibody in several fields, including Cytokine, Myeloid, CD8, Epitope and Immunotherapy. His research in Antibody intersects with topics in Cell biology, Effector and Angiogenesis.
His Cell biology study integrates concerns from other disciplines, such as Molecular biology, Transfection and Cell membrane. His research ties Cytotoxicity and Immunology together. His studies deal with areas such as T cell, Immune system, Cell and Cancer as well as Cancer research.
Martin J. Glennie spends much of his time researching Monoclonal antibody, Antibody, Immunology, Cell biology and Cytotoxic T cell. His biological study focuses on Isotype. Martin J. Glennie is interested in Antibody variable region, which is a field of Antibody.
His study connects Receptor and Immunology. Martin J. Glennie combines subjects such as Immune system, CD8 and Major histocompatibility complex with his study of Cytotoxic T cell. His Immune system research is multidisciplinary, incorporating elements of Antigen and CD40.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the welfare and use of animals in cancer research
P Workman;E O Aboagye;F Balkwill;A Balmain.
British Journal of Cancer (2010)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Jessica L. Teeling;Wendy J.M. Mackus;Luus J.J.M. Wiegman;Jeroen H.N. van den Brakel.
Journal of Immunology (2006)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignatio Melero;Sandra Hervas-Stubbs;Martin Glennie;Drew M. Pardoll.
Nature Reviews Cancer (2007)
Human monoclonal antibodies against cd20
Jessica Woodmill Cottage Teeling;Sigrid Ruuls;Martin Glennie;Jan G. J. Van De Winkel.
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan.
Mechanisms of killing by anti-CD20 monoclonal antibodies.
Martin J. Glennie;Ruth R. French;Mark S. Cragg;Ronald P. Taylor.
Molecular Immunology (2007)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Mark S. Cragg;Martin J. Glennie.
Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
A Tutt;G T Stevenson;M J Glennie.
Journal of Immunology (1991)
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
R.R. French;H.T.C. Chan;A.L. Tutt;M.J. Glennie.
Nature Medicine (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: